Production (Stage)
Avalo Therapeutics, Inc.
AVTX
$3.75
-$0.16-4.09%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -69.59% | -77.09% | -63.56% | -95.24% | -91.64% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -69.59% | -77.09% | -63.56% | -95.24% | -91.64% |
| Cost of Revenue | 288.59% | 53.57% | -31.41% | -80.73% | -77.99% |
| Gross Profit | -421.65% | -84.92% | 25.65% | 6.34% | 44.00% |
| SG&A Expenses | 81.66% | 67.37% | 38.74% | 13.27% | -8.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 137.94% | 62.85% | 4.33% | -38.91% | -50.09% |
| Operating Income | -153.08% | -74.35% | -9.69% | -7.24% | 21.67% |
| Income Before Tax | 151.19% | -11.05% | 75.97% | -46.36% | -383.70% |
| Income Tax Expenses | 784.62% | 714.29% | -129.03% | -53.57% | -50.00% |
| Earnings from Continuing Operations | 151.10% | -11.37% | 76.02% | -46.25% | -383.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 151.10% | -11.37% | 76.02% | -46.25% | -383.32% |
| EBIT | -153.08% | -74.35% | -9.69% | -7.24% | 21.67% |
| EBITDA | -153.75% | -74.80% | -9.76% | -7.25% | 21.89% |
| EPS Basic | 99.13% | 62.60% | 75.97% | 65.48% | 54.71% |
| Normalized Basic EPS | 101.30% | 72.32% | 82.92% | 73.28% | 59.94% |
| EPS Diluted | 96.54% | 61.37% | 72.95% | 62.57% | 53.27% |
| Normalized Diluted EPS | 100.59% | 71.79% | 82.60% | 73.28% | 59.94% |
| Average Basic Shares Outstanding | 2,487.66% | 3,508.12% | 8,868.64% | 13,511.64% | 1,053.09% |
| Average Diluted Shares Outstanding | 2,760.47% | 3,980.28% | 10,403.72% | 13,511.64% | 1,053.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |